Lek

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lek

Quick Facts

Property Description
Active ingredient Levofloxacin
Form Tablet, Infusion Solution, Ophthalmic Solution
Pharmacological class Fluoroquinolone Antibiotic
General purpose Antimicrobial therapy
Origin Synthetic

What is Lek? Definition, Class, and Composition

Lek is a synthetic pharmaceutical preparation whose single active ingredient is Levofloxacin, a potent and broad-spectrum antibacterial agent. Levofloxacin is formally classified as a second-generation fluoroquinolone antibiotic, a type of medicine specifically designed to combat bacterial pathogens within the body.

The drug is a prescription-only medicine (POM) that stems from chemical synthesis, representing the isolated L-isomer of the older quinolone drug Ofloxacin. This specific chemical structure enhances its efficacy against a wide range of susceptible bacteria, a property clinically recognized for supporting broad antimicrobial coverage. As a single-ingredient product, Lek focuses its therapeutic action entirely through the mechanism of Levofloxacin, and it is a commercially available brand name for this compound.


Lek: Understanding Its High-Level Purpose

The fundamental purpose of Lek is to provide antimicrobial therapy by decisively eliminating pathogenic bacteria responsible for various systemic bacterial infections. Its mode of operation is strictly bactericidal, meaning the drug directly kills the bacterial pathogens rather than simply inhibiting their ability to reproduce.

This bactericidal activity is achieved by interfering with the bacteria's core genetic processes, specifically blocking the critical enzymes—DNA gyrase and topoisomerase IV—that the microbe requires for DNA management and cell division. This mechanism allows the drug to effectively stop the bacterial cell from making new genetic material. This distinct action ensures the rapid and effective termination of the microbial life cycle, serving as an effective means to clear the body of a pathogenic bacterial burden and is typically used in cases requiring definitive bacterial eradication.


Available Forms and Differentiation

Lek is available across multiple physical forms to support targeted delivery, ensuring the active ingredient, Levofloxacin, can reach the site of infection. These forms include the tablet for oral administration, a sterile solution for infusion for intravenous delivery, and an ophthalmic solution for topical application to the eye.

The availability of these different formulations ensures the drug can be used in diverse clinical scenarios, providing the required therapeutic concentration whether the need is systemic (internal clearance of infection) or local (surface treatment). The manufacturing and marketing of Lek, similar to other major Levofloxacin brands like Tavanic and Levaquin, focus on this essential multi-form utility which supports treatment flexibility. All forms rely on the same active compound, confirming the substance's synthetic origin through pharmaceutical chemical synthesis.

Regulatory References

  1. NIH - Levofloxacin

What side effects are possible with Lek?

Possible Side Effects and Safety Information

The safety characteristics of Lek, which contains the active ingredient Levofloxacin, are formally classified by regulatory authorities based on the frequency of documented adverse reactions and the specific body systems affected. Side effects are organized into categories, ranging from common to rare and those where the frequency is not known.

Officially listed common adverse reactions include effects such as nausea, diarrhea, headache, dizziness, and insomnia. These are typically related to the Gastrointestinal and Nervous systems, as per regulatory documentation.


Serious and Potentially Irreversible Reactions

Official labeling emphasizes the potential for serious, disabling, and occasionally irreversible adverse reactions. These include:

  • Tendon Rupture (often the Achilles tendon) and Tendinitis.
  • Peripheral Neuropathy (nerve damage, which can be rapid in onset).
  • Severe Central Nervous System effects (including convulsions and psychotic reactions).
  • Severe events in the Cardiac (QT interval prolongation) and Vascular systems (Aortic aneurysm and dissection).

These severe reactions are classified within the Rare or Not Known frequency categories, affecting the Musculoskeletal, Nervous, and Cardiovascular System-Organ Classes.


Safety Considerations and Patterns

The regulatory profile highlights specific safety patterns, including that tendon rupture can occur during treatment or up to several months after discontinuation. The risk of tendon injury is specifically noted as being increased in older adults and when co-administered with corticosteroid medications. Additionally, patients are advised of the potential for photosensitivity, requiring avoidance of strong sunlight during treatment and for 48 hours following the final dose. Close monitoring of blood sugar is also noted for diabetic patients taking specific concomitant medications due to the risk of hypoglycemia.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Levofloxacin (Lek) overdose is defined by specific clinical manifestations and mandated emergency actions. Acute overexposure is documented to present with central nervous system (CNS) and gastrointestinal effects, including dizziness, disorientation, drowsiness, nausea, vomiting, and slurred speech.

Regulatory authorities place critical emphasis on severe outcomes that necessitate urgent medical intervention. These life-threatening manifestations include convulsions or seizures, dangerous prolongation of the heart’s QT interval (carrying the risk of Torsade de Pointes), and serious systemic effects such as tendon rupture or severe hepatotoxicity.

In the event of a suspected overdosage or the appearance of any of these severe signs, regulatory guidance is explicit: Levofloxacin must be discontinued immediately, and the patient must seek immediate medical attention. The official management strategy is strictly symptomatic and supportive because no specific antidote is known. Due to the documented risks, specialized monitoring, such as ECG observation, is required for managing cardiac effects. Official labeling also notes that older patients and those with renal impairment are documented to be at a heightened risk of toxicity, a crucial factor in the assessment of overdose severity.

Therapeutic Uses of Lek

Lek is commonly used to provide antimicrobial therapy for conditions involving bacterial infections, generally supporting the patient by directly addressing the source of acute illness. Its use is considered relevant in clinical situations requiring broad-spectrum coverage and is applied in addressing symptoms that interfere with daily comfort. This medication is used to treat a variety of bacterial infections, but not those caused by viruses like the common cold.

It is commonly used across three primary therapeutic domains: conditions involving respiratory symptoms (like pneumonia and acute bronchitis exacerbations), conditions involving complicated urinary and kidney symptoms, and conditions involving complex bacterial skin and soft tissue symptoms.

Conditions Involving Systemic and Respiratory Symptoms

This domain covers Lek's use in conditions involving bacterial infections where symptoms relate to systemic imbalance, including high fever and malaise, and acute respiratory distress. The core benefit is targeted bacterial clearance, which generally assists with maintaining functional stability and contributes to easing the overall symptom load associated with heightened physiological stress.

“The primary goal of this therapy is targeted pathogen clearance, which supports the patient’s ability to cope more steadily with heightened symptoms.”

Quick Fact: Supportive Relief for Symptoms of Discomfort Symptom Focus Context of Use Core Benefit
High fever & malaise Acute, severe infections Assists with maintaining functional stability
Painful urination Complicated UTIs Helps improve day-to-day comfort
Redness & swelling Deep skin infections Eases localized inflammatory distress

Conditions Involving Urinary and Deep Skin Symptoms

Lek is commonly applied in addressing complicated urinary tract symptoms (UTIs), including acute pyelonephritis, and complex skin symptoms such as cellulitis. In these areas, it is relevant for easing acute localized inflammatory distress. The practical benefit is supportive relief for pain and inflammation, which helps improve day-to-day comfort and may assist with managing the potential for symptoms to create noticeable physiological strain. The medication is also utilized in highly specialized scenarios, such as post-exposure management for specific bacterial agents, or supports the benefit of targeted pathogen clearance in challenging contexts, and is applied locally for managing surface bacterial conjunctivitis in the eye.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility Profile: Who Can and Cannot Use Lek?

This section outlines the specific population eligibility and restrictions documented in official government regulatory documents.

Population Status Regulatory Rule (Official Label Terminology)
Must Not Use (Contraindicated) Documented Hypersensitivity to the active substance or excipients. Patients with Severe Renal or Hepatic Impairment. Individuals under a specific age threshold, such as those under 18 years of age.
Use Not Recommended Patients who are pregnant or breastfeeding (unless benefits clearly outweigh risks as determined by a healthcare provider).
Conditional/Restricted Use The Elderly (Geriatric) and patients with moderate organ impairment may use the medicine but require initial dose reduction and close monitoring.

Official regulatory documents define absolute non-eligibility (Contraindications) based on immediate life-threatening risk factors, such as known hypersensitivity or specific genetic profiles. Other factors, like the patient's age (Paediatric Use) or physiological state (Pregnancy and Lactation), result in a Not Recommended status when safety and efficacy data are not officially established. These criteria ensure the medicine is restricted only to populations where its safety profile has been governmentally verified.

What should I know about interactions with other medicines?

The official interaction profile for Lek (Levofloxacin) is defined by pharmacokinetic and pharmacodynamic interactions documented in regulatory prescribing information.

Pharmacokinetic Interaction Constraints

Oral Levofloxacin absorption is significantly decreased by multivalent cation-containing products, including antacids (magnesium/aluminum), Sucralfate, and iron or zinc supplements. This reduction in bioavailability is due to chelation, requiring a mandatory timing separation. The oral dose must not be taken within two hours before or two hours after these interacting substances.

Separately, agents that inhibit renal tubular secretion, specifically Probenecid and Cimetidine, officially reduce the renal clearance of Levofloxacin. While this increases overall plasma exposure, dosage adjustments are generally not warranted; however, this is a relevant factor for patients with renal impairment.

Pharmacodynamic Interaction Risks

Certain co-administrations carry an officially documented additive risk:

  • Contraindicated Combinations: Co-administration with specific drugs that prolong the QT interval, such as Dronedarone, Pimozide, and Thioridazine, is prohibited due to the risk of cardiac toxicity.
  • Enhanced Effects: Levofloxacin may enhance the anticoagulant effect of Warfarin, requiring the monitoring of INR and prothrombin time. It may also lead to disturbances in blood glucose levels when co-administered with antidiabetic agents.
  • CNS and Musculoskeletal Risks: Co-administration with NSAIDs or Theophylline carries a documented risk of increasing Central Nervous System stimulation. Furthermore, the risk of tendon disorders is officially increased when Levofloxacin is combined with systemic corticosteroids, with specific regulatory caution noted for the elderly population.

Mechanism of Action

Lek's mechanism is fundamentally defined by its cell-killing mechanism resulting from direct interference with the bacterial cell's core genetic machinery.

Targeted Blockade of Essential Bacterial Enzymes

Lek (Levofloxacin) functions as a dual inhibitor, engaging two critical bacterial enzymes: DNA gyrase and Topoisomerase IV. By binding to and trapping the complex formed by the enzyme and the bacterial DNA, the drug prevents the enzymes from successfully completing their job of cutting and re-joining DNA strands. This molecular intervention is the primary step in the drug's mechanism, focusing on essential microbial genetic maintenance.

Lethal Cascade of Irreparable Genomic Damage

The physical blockade of these enzymes triggers a cascade resulting in the rapid accumulation of DNA double-strand breaks (DSBs) and the failure of chromosome partitioning necessary for cell division. This genomic damage rapidly exceeds the bacteria's ability to engage effective repair mechanisms, leading to severe cellular stress and the process of cellular demise. This cell-killing action is the core physiological consequence of the mechanism.

Dosage and Administration Information

Official Administration Guidelines for Lek (Levofloxacin)

Lek is administered through multiple routes, including Oral (tablets or solution), Intravenous (IV) Infusion, and Topical (ophthalmic solution). The dosage and duration are specific to the condition and must be determined from official labeling.

Category Administration Rule
Dosing Frequency Primarily Once Daily (every 24 hours) for systemic use. Pediatric patients (where approved) may require a twice-daily regimen.
Oral Administration Tablets may be taken with or without food. Oral Solution should be taken on an empty stomach (e.g., 1 hour before or 2 hours after meals). Tablets must be swallowed whole or may be divided at the score line if specified for dose adaptation.
IV Infusion Must be administered only by slow IV infusion. The infusion time must be observed: generally 60 minutes for 500 mg and 90 minutes for 750 mg doses.
Administration Timing Oral formulations must be taken at least two hours before or two hours after products containing multivalent cations, such as antacids, iron salts, or sucralfate, as specified in regulatory documents.
Dose Adjustment Mandatory dose adjustment is required for adult patients with renal impairment (creatinine clearance < 50 mL/min), involving reduced doses and/or extended dosing intervals (e.g., every 48 hours). No adjustment is required for impaired liver function.

If a dose is missed, it should be taken as soon as remembered, unless the next dose is due within a specific timeframe (e.g., 8–12 hours), in which case the missed dose should be skipped to resume the regular schedule.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lek (Levofloxacin)

Evidence for Use in Acute Respiratory Infections (Pneumonia and Bronchitis)

Research exploring Lek's use in acute respiratory conditions, which are conditions involving periods of heightened symptoms, primarily consists of short-term Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies included adult patients with community-acquired pneumonia (CAP) and those experiencing an acute bacterial flare-up of chronic bronchitis (ABECB). The research examined outcomes related to physical discomfort and systemic or functional imbalance, such as resolution of fever, cough, and other signs of acute illness, as well as clearance of the bacteria causing the infection.

Findings describe patterns observed in the studies where trials documented the measurement of clinical response criteria by the end of the treatment period. Studies monitored the rates of bacterial clearance. Research highlights changes measured during the study period, with some trials exploring shorter treatment durations compared to conventional ones. Evidence also contributes to the broader evidence landscape by including active-control arms for comparison against other standard treatments.


Evidence for Use in Complicated Urinary Tract and Kidney Infections

Lek was studied for use in complicated urinary tract infection (cUTI) and acute pyelonephritis (AP), which are conditions associated with acute or disruptive episodes and outcomes linked to inflammatory or irritative states. The evidence base includes RCTs and Meta-analyses that observed patient populations, including adults with structural or functional abnormalities of the urinary tract. These studies monitored both the clinical success (resolution of urinary symptoms) and the microbiological outcomes (clearance of the infectious bacteria).

Studies reported how symptoms evolved in the observed populations, and trials exploring short-term changes documented rates of bacterial eradication consistent with the study protocol. Trials documented the measurement of clinical response criteria by the end of the treatment period. Comparative studies reported patterns of clinical response consistent with those observed in the specific comparator arms. Research highlights changes measured during the study period, including the success of short-course treatment plans compared to longer, conventional regimens.


What is Still Uncertain About Lek's Research

The evidence highlights what is known — and what is still uncertain. Certainty remains low regarding the long-term patterns of infection recurrence or the sustained absence of acute symptoms, as follow-up durations were limited in many studies. A major area of uncertainty is the continuous emergence of bacterial resistance, where research is ongoing to monitor how patterns related to resistance evolve across different regions and populations. The evolving nature of resistance patterns means that the research provides context, but the data do not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Lek (FAQ)


Q: How quickly does Lek start working after I take it?

Official regulatory documents indicate that Lek is rapidly and almost completely absorbed after a person takes it orally. Peak levels of the medicine in the blood are generally reached within one to two hours after dosing. However, the time it takes for a person to feel a measurable improvement in their symptoms can vary depending on the type and severity of the infection.


Q: How is Lek different from similar over-the-counter medicines?

Lek is classified as a potent fluoroquinolone antibiotic, which is a prescription-only medicine. Its purpose is to actively kill systemic bacterial pathogens responsible for specific infections. This fundamentally differs from most over-the-counter medicines, which are primarily used to treat symptoms, like pain or fever, and are not designed to eradicate bacteria.


Q: Does Lek affect sleep patterns?

Yes, official documentation lists insomnia (difficulty sleeping) as a common side effect of Lek. Furthermore, post-marketing reports have noted the potential for other Central Nervous System effects, including unusual or vivid nightmares.


Q: How long can a person safely stay on Lek?

The length of treatment with Lek is determined by the specific type of infection being treated. Official dosing schedules outline treatment durations that can vary considerably. Regulatory information indicates the drug is intended for use only for the duration specified in the product labeling for the specific condition.


Q: What happens if I miss a dose of Lek?

Regulatory documents caution that failing to take the drug exactly as prescribed carries a risk of reduced treatment effectiveness against the infection. Inconsistent dosing can also increase the chance of the targeted bacteria developing resistance to the antibiotic.


Q: Can elderly patients safely use Lek?

Lek can be used by the geriatric population, but official labeling notes that special consideration is often required. Older adults are noted to have an elevated risk of certain serious side effects, specifically tendon disorders and issues related to QT interval prolongation (a heart-related effect).


Q: What are the major concerns for people with kidney issues taking Lek?

Official guidelines state that a mandatory dose adjustment (either a reduced dose or an extended interval between doses) is required for adult patients with impaired kidney function. This adjustment is necessary because the drug's elimination is reduced in patients with kidney impairment.


Q: What is the typical duration of treatment with Lek?

The duration of therapy is dependent on the infection being targeted, its severity, and the patient's response. Typical courses cited in official regulatory information often range between three to 14 days. The precise duration should align with the official product labeling and a healthcare provider's evaluation.


Q: Does Lek need to be taken with food?

The guidance depends on the formulation of the medicine. Official administration guidelines state that oral tablets can be taken independent of meals. However, the oral solution should be taken on an empty stomach to ensure proper absorption.


Q: Is it necessary to have regular blood tests while on Lek?

Routine blood tests are not necessary for all patients taking Lek. However, official information notes that blood monitoring, such as checking INR/Prothrombin Time, is typically indicated when the drug is taken with the anticoagulant Warfarin. Monitoring of blood sugar is also relevant with certain antidiabetic agents.


Q: Does Lek interfere with birth control pills?

While Levofloxacin itself is not always directly cited, antibiotics as a class may potentially reduce the effectiveness of estrogen-containing medications, such as some birth control pills. Official information for hormonal contraceptives may contain specific guidance on co-administration with antibiotics, and patients should refer to their contraceptive's product information.


Q: Can Lek be taken with antacids like Tums?

Yes, but with mandatory timing separation. Products containing multivalent cations (like antacids containing magnesium or aluminum) should be separated by at least two hours before and two hours after the oral dose of Lek. This is necessary because these products can significantly bind the drug, reducing its absorption.


Q: Are there different dosages of Lek, and why?

Yes, Lek is available in different strengths, such as 250 mg, 500 mg, and 750 mg oral doses. The specific dose chosen is determined by the particular type and severity of the infection being treated, as well as the patient's kidney function.


Q: How should Lek be stored?

Official labeling states that Lek should be stored at controlled room temperature, typically around 20 C to 25 C. It must be protected from excessive heat, moisture, and direct light to maintain its stability and effectiveness. The medicine should always remain in its original, protective container until use.


Q: Are there any long-term side effects associated with Lek?

Official warnings note that certain serious side effects, such as damage to the nerves (peripheral neuropathy) and tendon rupture, may be disabling and potentially irreversible. Notably, tendon rupture can occur not only during treatment but also up to several months after the medicine has been stopped.


Q: Can Lek cause changes in mood or anxiety?

Yes, regulatory documents list a range of Central Nervous System (CNS) effects that have been reported as side effects. These include disturbances such as anxiety, confusion, agitation, paranoia, and depression.


Q: Do many people experience the 'rare' side effects of Lek?

Side effects classified as 'rare' mean that based on clinical trials or post-marketing surveillance, they have occurred in less than 1 in 1,000 patients. Therefore, while these serious effects are officially noted in regulatory documents, they are statistically not common.


Q: Can children or teenagers take Lek?

The use of Lek in children (under 18) is generally restricted to specific, severe infections where the benefits are determined to outweigh the risks, as detailed in the official product labeling. This restriction is due to concerns about potential musculoskeletal toxicity (joint and tendon issues).


Q: Is Lek safe to use before driving or operating machinery?

Official labeling advises caution, as the drug can cause side effects like dizziness, confusion, hallucinations, and lightheadedness. Patients should observe how the medicine affects them, as side effects could impair the ability to safely drive or operate heavy machinery.


Q: Does the effectiveness of Lek decrease over time?

Studies show that the way the drug is handled by the body (pharmacokinetics) is predictable even after multiple doses. However, the effectiveness can be compromised if the full prescribed course is not completed, which can lead to the bacteria becoming resistant to the drug.


Q: Can Lek be crushed or split if the pill is too large?

Oral tablets should be swallowed whole with water. They may only be divided at the score line if specified by the product information for the purpose of a specific dose adaptation. Crushing the tablet is generally not supported by official administration guidelines.


Q: Is a dry mouth a common but minor side effect of Lek?

While not always listed as a common effect in core documents, the side effect dry mouth (xerostomia) has been flagged as a potential safety signal in some international post-marketing surveillance data.


Q: Why do some people say Lek didn't work for them?

Treatment failure may occur for several reasons, as noted in patient counseling information. The most common reasons include an infection caused by bacteria that are already resistant to the drug, or not completing the full prescribed course of medication as directed.


Q: Is Lek safe for people with liver disease?

The drug is minimally metabolized by the liver, meaning its processing by the body is not expected to be significantly affected by typical liver impairment. However, severe liver impairment is generally considered a contraindication or requires careful consideration according to product labeling.


Q: Why does Lek require a prescription?

Lek is classified as a prescription-only medicine (POM) because its potent activity and potential for serious adverse effects necessitate supervision. Its classification is due to the need for a professional diagnosis and evaluation of the individual's specific health condition.


Q: Is the research for Lek mainly focused on one specific patient group?

Clinical studies supporting the drug's initial approval focused on specific adult populations. These included adults diagnosed with community-acquired pneumonia, acute bacterial flare-ups of chronic bronchitis, and complicated urinary tract and kidney infections.


Q: Are there any foods or drinks that should be avoided while taking Lek?

Yes, foods and drinks containing high levels of multivalent cations must be separated from the oral dose by at least two hours before and two hours after. This includes mineral supplements and dairy products that are highly fortified with calcium, which can reduce the medicine's absorption.


Q: Is Lek available as a generic medicine?

Yes, the active ingredient in Lek, Levofloxacin, is available as a generic medicine. Regulatory bodies have approved generic versions in various forms, including tablets, oral solutions, and injectable solutions, following the brand-name patent expiration.


Q: What should I do if my side effects don't go away after a week on Lek?

Official documentation advises discontinuing the drug immediately and seeking medical attention for signs of serious, disabling, or potentially irreversible side effects. This instruction applies regardless of how long the person has been taking the medication.


Q: Are there any vitamins or supplements that interact badly with Lek?

Yes, official labeling notes that supplements and multivitamins that contain iron, zinc, or calcium can interfere with the absorption of the oral dose. The oral dose must be separated from these supplements by at least two hours before or two hours after the administration of Lek.

How should Lek be stored and disposed of?

How to Store and Dispose of Lek?

Official regulatory documentation defines precise requirements for the storage, handling, and disposal of Lek to maintain its stability and effectiveness.

Storage Requirements

  • Temperature and Protection: Store Lek exactly as specified on the product labeling, often requiring a specific temperature range (e.g., controlled room temperature or refrigeration) and protection from moisture, excessive heat, and light. The medicine must remain in its original, protective container until use.
  • In-Use Stability: If Lek is reconstituted or opened, use or discard it within the period specified on the label to ensure product quality.

Disposal Requirements

  • Unused Medication: Expired or unused Lek should be disposed of via an authorized drug take-back program. Following this regulatory guidance is the preferred method for safe disposal.
  • Household Disposal: If a take-back program is unavailable, follow the specific instructions on the labeling. If no instructions are provided and the medicine is not on the FDA's flush list, mix it with an unappealing substance (like used coffee grounds), seal it in a plastic bag, and place it in the household trash. Keep all medicines out of the reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lek found in:

A-Z Index: